CA-PULMONX
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) this week issued a substantial revision to its management recommendations for chronic obstructive pulmonary disease (COPD) that, for the first time, includes bronchoscopic lung volume reduction using endobronchial valves as a treatment option for patients with advanced emphysema and absence of collateral ventilation. The updated recommendations are based on new clinical evidence published in the past 15 months supporting the Zephyr® Endobronchial Valve (EBV), including three randomized controlled trials (BeLieVeR-HIFi , STELVIO and IMPACT ).
In describing the clinical evidence to support this recommendation, the GOLD report notes, “In select patients with advanced emphysema, bronchoscopic interventions reduce end-expiratory lung volume and improves exercise tolerance, health status and lung function 6-12 months following treatment.“
“This is the first major update to the GOLD guidance for bronchoscopic interventions, based on recent data,” said Professor Felix Herth, Head of the Department of Internal Medicine, Pulmonology and Critical Care Medicine, Thoraxklinik Heidelberg, Germany. “These interventions offer promise for emphysema patients who continue to suffer symptoms, despite optimal pharmacologic management.”
Zephyr EBVs are tiny, minimally-invasive, one-way valves placed in select airways of the lungs to occlude diseased regions and reduce lung hyperinflation. As a result, the remaining healthier regions may function more efficiently, enabling better breathing and an improved quality of life for patients.
Each year, GOLD issues a report entitled “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease,” which is used worldwide as a “strategy” document for healthcare professionals to implement effective management programs based on local healthcare systems. The report issues recommendations for the management of COPD based on the best scientific information available.
“With our tools to help physicians identify the best responders to endobronchial valve treatment, Pulmonx is enabling precision medicine for the treatment of emphysema,” said Glen French, Pulmonx chief executive officer. “We welcome this recognition of the growing body of evidence demonstrating the benefit of EBV treatment for emphysema patients.”
Over the past 10 years, more than 48,000 Zephyr EBVs have been implanted globally in more than 12,000 patients. To view a video of the Zephyr EBV procedure, click here .
About Pulmonx
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide. For more information, visit www.pulmonx.com .
The Zephyr EBV is an investigational device in the United States. Limited by U.S. law to investigational use only.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161118005704/en/
Contact:
Chronic Communications
Michelle McAdam, (949) 545-6654 or (310)
902-1274
michelle@chronic-comm.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Logical Intelligence Introduces First Energy-Based Reasoning AI Model, Signals Early Steps Toward AGI, Adds Yann LeCun and Patrick Hillmann to Leadership21.1.2026 19:21:00 CET | Press release
Logical Intelligence, an artificial intelligence company developing energy-based (EBM) reasoning systems, today announced that Kona 1.0, its pioneering EBM for reasoning, will enter pilot programs with select partners in the energy, advanced manufacturing, and semiconductor industries later this quarter. Logical Intelligence also released a live demonstration of Kona 1.0 on its website, beginning with head-to-head sudoku challenges against leading large language models. Additional demonstrations, including chess and Go, are planned. The company said the goal is to give researchers and the public a clear view into how energy-based reasoning differs from probabilistic systems. “Kona learns by recognizing and correcting its own mistakes, rather than guessing the most likely answer,” said Eve Bodnia, founder and CEO of Logical Intelligence. “If general intelligence means the ability to reason across domains, learn from error, and improve without being retrained for each task, then we are s
Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership21.1.2026 17:35:00 CET | Press release
Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the termination of a 2014 neuromodulator research & development partnership with Ipsen. The partnership was limited to the rights and obligations relating to the companies’ early-stage neuromodulator pipeline for aesthetic indications. Galderma welcomes the clarity provided by the arbitral tribunal. This decision has no impact on the commercialization of Galderma’s neuromodulator portfolio. Galderma will continue to commercialize and supply Dysport®/Azzalure®, Alluzience®, and RelfydessTM in all territories where it has regulatory approval and in accordance with our existing agreements with our partner Ipsen. Progressing on our path towards becoming the undisputed dermatology powerhouse Galderma remains focused on its ambition to become the world’s undisputed dermatology powerhouse across the full spectrum of a fast-growi
ThetaRay Appoints Financial Markets Technology Leader Brad Levy as Chief Executive Officer21.1.2026 17:00:00 CET | Press release
Former Symphony CEO to lead ThetaRay’s next phase of AI-driven category leadership in transaction monitoring and due diligence ThetaRay, a global leader in Cognitive AI financial crime compliance, today announced the appointment of Brad Levy as Chief Executive Officer. Levy, a leading financial markets infrastructure executive and former CEO of Symphony, will lead ThetaRay’s next phase of growth as the company continues to scale its Cognitive AI platform, now emerging as the leading AI strategy and technology for transaction monitoring and transaction due diligence, across banks and fintechs worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121002476/en/ ThetaRay Appoints Brad Levy as CEO Levy brings decades of experience building and leading mission-critical financial infrastructure at scale. Most recently, he served as CEO of Symphony, the financial markets infrastructure and technology platform established by a
HCL Group and UpLink Announce Winners of ‘Water Resilience Challenge’ Under the Aquapreneur Innovation Initiative21.1.2026 16:02:00 CET | Press release
10 Aquapreneurs selected from over 300 applicantsWinners showcased innovations across digital water management, biological breakthroughs, hardware solutions, deep-tech design, and community-driven modelsFinancial support of CHF 1.75 million available to scale initiativesAquapreneur Innovation Initiative: CHF 15 million commitment to global water challenges HCL Group, a leading global conglomerate, and UpLink, the World Economic Forum’s early-stage innovation initiative, have announced the winners of the ‘Water Resilience Challenge,’ the fourth in a series of five challenges under the five-year, CHF 15 million Aquapreneur Innovation Initiative launched by HCL Group. The announcement marks a significant step in the ongoing mission to address global water challenges through innovation and entrepreneurship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121697759/en/ Roshni Nadar Malhotra, Chairperson of HCL Group, congratula
illumynt Appoints Chris Tejeda as Chief Revenue Officer21.1.2026 15:47:00 CET | Press release
illumynt today announced the promotion of Chris Tejeda to Chief Revenue Officer (CRO), reflecting the company’s continued growth and expanding global footprint. In his new role, Tejeda will lead illumynt’s global revenue strategy, customer engagement, and strategic partnerships as demand accelerates for secure, technology-driven IT Asset Disposition (ITAD) solutions. “Chris has been instrumental in aligning our commercial strategy with the evolving needs of hyperscale and enterprise customers,” said CEO Joerg Herbarth. “As AI accelerates infrastructure refresh cycles and raises the bar for security and compliance, his leadership will be critical to scaling illumynt with focus, transparency, and customer trust.” Tejeda brings extensive experience in enterprise technology services and has played a key role in illumynt’s recent momentum, including significant revenue growth and the expansion of advanced capabilities across AI/GPU diagnostics, automation, and value recovery. View source ve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom